Eledon Pharmaceuticals, Inc.

What they do

Eledon targets the CD40 Ligand pathway to develop immunomodulatory therapies that protect transplanted organs and prevent rejection. Its lead compound, tegoprubart, is an IgG1 anti-CD40L antibody designed to block CD40L rather than the CD40 receptor, inhibiting CD40 and CD11 costimulatory signaling and increasing polarization of CD4+ lymphocytes to Tregs. The company acquired the tegoprubart intellectual property through its September 2020 acquisition of Anelixis Therapeutics, after discontinuing legacy ENT assets.

Revenue drivers

• Tegoprubart in kidney transplantation — Lead program and primary focus of resources since January 2023; evaluated in a Phase 1b trial, a Phase 2 open-label extension, and the Phase 2 BESTOW trial. No revenue is generated; value depends on planned Phase 3 advancement.
• Tegoprubart in islet cell transplantation — Investigator-initiated University of Chicago Medicine study in type 1 diabetes; company-funded islet cell program was discontinued in January 2023 but an investigator study continued. No revenue.
• Tegoprubart in ALS — Clinical development is committed but cannot continue without additional financing, per both the 10-K and 10-Q. No revenue.
• Xenotransplantation collaboration with eGenesis — Supports preclinical and clinical studies in kidney, heart, and islet cell transplantation. No revenue disclosed.

Recent performance

All reported annual revenue is $0.00; net loss was $45.6M in 2025 versus $36.2M in 2024, and operating cash flow was -$62.3M in 2025 versus -$47.3M in 2024. Diluted EPS improved to -$0.52 in 2025 from -$0.66 in 2024, largely reflecting share count changes. At June 30, 2026, total assets were $126.1M, total liabilities $54.1M, and shareholder equity $33.0M, while the Q2 2026 earnings release reported cash, cash equivalents and short-term investments of $88.8M. The 8-K of August 13, 2026 disclosed a successful End-of-Phase 2 FDA meeting supporting a global Phase 3 kidney transplantation trial on track to initiate in late 2026.

Strategy

Eledon's stated strategy is to optimize the clinical and commercial value of tegoprubart and build a focused immunology franchise. It prioritizes allograft and xenograft organ and cell transplantation, and is seeking FDA guidance on a potential Phase 3 kidney transplantation trial. The planned global Phase 3 would enroll approximately 600 patients with a primary non-inferiority endpoint versus tacrolimus at 52 weeks based on biopsy-proven acute rejection, graft loss, and death. The company has partnered with Natera to use the Prospera dd-cfDNA assay exclusively in that planned trial. ALS development remains committed but unfunded without additional financing.

Risks

• No product revenue and recurring losses — Eledon has reported $0.00 annual revenue across all years shown and net losses of $45.6M in 2025 and $36.2M in 2024, with operating cash use rising to $62.3M in 2025.
• Need for additional financing — The company states it cannot continue ALS clinical development of tegoprubart without additional funding, and cash, cash equivalents and short-term investments were $88.8M at June 30, 2026.
• Clinical and regulatory uncertainty — The planned Phase 3 kidney transplantation trial has not started; it is described as on track to initiate in late 2026 and depends on regulatory feedback and alignment.
• Dependence on a single lead compound — Substantially all value rests on tegoprubart, and the company discontinued or deprioritized other programs including company-funded islet cell transplantation, IgAN, and legacy ENT assets.

Outlook

Management anticipates initiating a global Phase 3 trial of tegoprubart in kidney transplantation in late 2026, enrolling approximately 600 patients. It also plans to support an investigator-led study in renal dysfunction patients receiving an islet cell transplant in 2026 and to initiate a company-sponsored registration-path study in islet cell transplantation. Further ALS development requires additional financing.